BACKGROUND AND PURPOSE: Treatment options for recurrent high-grade glioma after a complete course of radiotherapy comprise surgery, reirradiation and chemotherapy but the efficacy of any of the given salvage treatments is limited. In order to further define the role of short-term radiotherapy as retreatment option for selected patients, we analyzed outcomes after treatment with a hypofractionated radiation. PATIENTS AND METHODS: Treatment outcomes (overall survival and treatment-associated toxicity) were analyzed retrospectively in 31 patients treated between 1994 and 2007. Hypofractionated radiotherapy was performed after three-dimensional CT planning with a median total dose of 20 Gy in a single department. RESULTS: With a median interval of 20 months from primary radiotherapy, two grade III and 29 grade IV tumors were reirradiated. Pretreatment consisted of surgery and involved-field radiotherapy (median 59 Gy). 77% of the patients received additional chemotherapy before the second course of radiotherapy, and 48% were treated after secondary resection. The median overall survival after hypofractionated radiotherapy was 10.2 months, and the median overall survival time after primary diagnosis 30.9 months. No severe toxicity was observed. CONCLUSION: Hypofractionated reirradiation with 20 Gy given over 1 week is a practicable and well-tolerated treatment option for patients with recurrent malignant glioma. The overall survival was comparable to the reported outcomes from other series including those with longer treatment protocols.
BACKGROUND AND PURPOSE: Treatment options for recurrent high-grade glioma after a complete course of radiotherapy comprise surgery, reirradiation and chemotherapy but the efficacy of any of the given salvage treatments is limited. In order to further define the role of short-term radiotherapy as retreatment option for selected patients, we analyzed outcomes after treatment with a hypofractionated radiation. PATIENTS AND METHODS: Treatment outcomes (overall survival and treatment-associated toxicity) were analyzed retrospectively in 31 patients treated between 1994 and 2007. Hypofractionated radiotherapy was performed after three-dimensional CT planning with a median total dose of 20 Gy in a single department. RESULTS: With a median interval of 20 months from primary radiotherapy, two grade III and 29 grade IV tumors were reirradiated. Pretreatment consisted of surgery and involved-field radiotherapy (median 59 Gy). 77% of the patients received additional chemotherapy before the second course of radiotherapy, and 48% were treated after secondary resection. The median overall survival after hypofractionated radiotherapy was 10.2 months, and the median overall survival time after primary diagnosis 30.9 months. No severe toxicity was observed. CONCLUSION: Hypofractionated reirradiation with 20 Gy given over 1 week is a practicable and well-tolerated treatment option for patients with recurrent malignant glioma. The overall survival was comparable to the reported outcomes from other series including those with longer treatment protocols.
Authors: Anita Mahajan; Ian E McCutcheon; Dima Suki; Eric L Chang; Samuel J Hassenbusch; Jeffrey S Weinberg; Almon Shiu; Moshe H Maor; Shiao Y Woo Journal: J Neurosurg Date: 2005-08 Impact factor: 5.115
Authors: Marc D Piroth; Bernd Gagel; Michael Pinkawa; Sven Stanzel; Branka Asadpour; Michael J Eble Journal: Strahlenther Onkol Date: 2007-12 Impact factor: 3.621
Authors: Dirk Vordermark; Oliver Kölbl; Klemens Ruprecht; Giles H Vince; Klaus Bratengeier; Michael Flentje Journal: BMC Cancer Date: 2005-05-30 Impact factor: 4.430
Authors: A A Brandes; A Tosoni; G Cavallo; R Bertorelle; V Gioia; E Franceschi; M Biscuola; V Blatt; L Crinò; M Ermani Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640
Authors: Christina Leitzen; Hans H Schild; Birgitta Bungart; Ulrich Herrlinger; Christiana Lütter; Thomas Müdder; Timo Wilhelm-Buchstab; Heinrich Schüller Journal: Strahlenther Onkol Date: 2010-11-29 Impact factor: 3.621
Authors: G Minniti; V Armosini; M Salvati; G Lanzetta; P Caporello; M Mei; M F Osti; R Enrici Maurizi Journal: J Neurooncol Date: 2010-11-05 Impact factor: 4.130
Authors: Joshua T McKenzie; Jess N Guarnaschelli; Achala S Vagal; Ronald E Warnick; John C Breneman Journal: J Neurooncol Date: 2013-04-16 Impact factor: 4.130
Authors: M Balducci; B Diletto; S Chiesa; G R D'Agostino; M A Gambacorta; M Ferro; C Colosimo; G Maira; C Anile; V Valentini Journal: Strahlenther Onkol Date: 2014-01-17 Impact factor: 3.621
Authors: Waqar Haque; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Milind Javle; Christopher R Garrett; Robert A Wolff; Prajnan Das Journal: Radiat Oncol Date: 2009-11-18 Impact factor: 3.481